Market closedADR
Silence Therapeutics/$SLN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Ticker
$SLN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
116
Website
SLN Metrics
BasicAdvanced
$192M
-
-$0.98
1.07
-
Price and volume
Market cap
$192M
Beta
1.07
52-week high
$5.28
52-week low
$3.99
Financial strength
Current ratio
11.138
Quick ratio
10.358
Total debt to equity
0.087
Management effectiveness
Return on assets (TTM)
-19.24%
Return on equity (TTM)
-58.08%
Valuation
Price to revenue (TTM)
4.341
Price to book
1.43
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-2.768
Growth
Revenue change (TTM)
36.71%
Earnings per share change (TTM)
-32.99%
3-year revenue growth (CAGR)
40.66%
3-year earnings per share growth (CAGR)
-16.19%
SLN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Silence Therapeutics stock?
Silence Therapeutics (SLN) has a market cap of $192M as of March 14, 2025.
What is the P/E ratio for Silence Therapeutics stock?
The price to earnings (P/E) ratio for Silence Therapeutics (SLN) stock is 0 as of March 14, 2025.
Does Silence Therapeutics stock pay dividends?
No, Silence Therapeutics (SLN) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Silence Therapeutics dividend payment date?
Silence Therapeutics (SLN) stock does not pay dividends to its shareholders.
What is the beta indicator for Silence Therapeutics?
Silence Therapeutics (SLN) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.